drugset / Trial / NCT05238844
A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in volunteers with chronic hepatitis B virus infection. Volunteers will be administered multiple oral doses of ATI-2173 vebicorvir in combination with tenofovir disoproxil fumarate and assessed for safety and efficacy including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the drug effects the virus infection.
Timeline
- Start
- 2022-04-11
- Primary completion
- 2022-05-25
- Completion
- 2022-05-25
Outcome
Outcome not reported
Stopped: “Sponsor stopped due to partner collaboration ending”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FOSCLEVUDINE ALAFENAMIDE | Other / unclassified | 25 mg | Oral |
| Subject | Vebicorvir | Small molecule | 300 mg | Oral |
| Background | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |